Floatz logo

bi 1701963

Metastatic Cancer

Mirati Therapeutics Inc.Phase 1Dormant
C
35/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
22/ 100
Competitive Position
73/ 100

Competitive context

276 Active assets in the Metastatic Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 3BB
Irinotecan
Incyte Corporation
Phase 3BB
FILGRASTIM
Mayo Clinic
Phase 3BB
Pembrolizumab
InSilico Medicine Hong Kong Limited
Phase 2/3BB
Cyclophosphamide
InSilico Medicine Hong Kong Limited
Phase 2/3BB

View all 50 →

Same molecule, other indications

bi 1701963 is also rated in:

Solid Tumors, KRAS MutationDormant
C
Indicative ·
37 / 100
View asset →
malignant colon neoplasmDormant
C
Indicative ·
37 / 100
View asset →
lung cancerDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →